ASH 2018 | Progress for gilteritinib and quizartinib for AML in the first-line setting

Mark Levis

The FLT3 inhibitors quizartinib and gilteritinib have made great progress in the relapsed/refractory acute myeloid leukemia (AML) space; however, they may be able to exert more of a benefit in the upfront setting, as discussed here by Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD. Dr Levis highlights the progress in the first-line setting for both of these drugs. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video